762 related articles for article (PubMed ID: 26338302)
1. Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura.
Tersteeg C; Schiviz A; De Meyer SF; Plaimauer B; Scheiflinger F; Rottensteiner H; Vanhoorelbeke K
Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2336-42. PubMed ID: 26338302
[TBL] [Abstract][Full Text] [Related]
2. [Thrombotic Thrombocytopenic Purpura --Pathophysiology and Assays of ADAMTS13 Activity].
Kato S; Fujimura Y
Rinsho Byori; 2015 Oct; 63(10):1228-36. PubMed ID: 26897861
[TBL] [Abstract][Full Text] [Related]
3. TTP and ADAMTS13: When Is Testing Appropriate?
Mannucci PM; Peyvandi F
Hematology Am Soc Hematol Educ Program; 2007; ():121-6. PubMed ID: 18024619
[TBL] [Abstract][Full Text] [Related]
4. ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies.
Tersteeg C; Verhenne S; Roose E; Schelpe AS; Deckmyn H; De Meyer SF; Vanhoorelbeke K
Expert Rev Hematol; 2016; 9(2):209-21. PubMed ID: 26581428
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in thrombotic thrombocytopenic purpura.
Sadler JE; Moake JL; Miyata T; George JN
Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
[TBL] [Abstract][Full Text] [Related]
6. Generation of Anti-Murine ADAMTS13 Antibodies and Their Application in a Mouse Model for Acquired Thrombotic Thrombocytopenic Purpura.
Deforche L; Tersteeg C; Roose E; Vandenbulcke A; Vandeputte N; Pareyn I; De Cock E; Rottensteiner H; Deckmyn H; De Meyer SF; Vanhoorelbeke K
PLoS One; 2016; 11(8):e0160388. PubMed ID: 27479501
[TBL] [Abstract][Full Text] [Related]
7. Thrombotic thrombocytopenic purpura and other thrombotic microangiopathic hemolytic anemias: diagnosis and classification.
Shenkman B; Einav Y
Autoimmun Rev; 2014; 13(4-5):584-6. PubMed ID: 24418304
[TBL] [Abstract][Full Text] [Related]
8. Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies.
Crawley JT; Scully MA
Hematology Am Soc Hematol Educ Program; 2013; 2013():292-9. PubMed ID: 24319194
[TBL] [Abstract][Full Text] [Related]
9. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
Peyvandi F; Lavoretano S; Palla R; Feys HB; Vanhoorelbeke K; Battaglioli T; Valsecchi C; Canciani MT; Fabris F; Zver S; Réti M; Mikovic D; Karimi M; Giuffrida G; Laurenti L; Mannucci PM
Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285
[TBL] [Abstract][Full Text] [Related]
10. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy.
Tersteeg C; de Maat S; De Meyer SF; Smeets MW; Barendrecht AD; Roest M; Pasterkamp G; Fijnheer R; Vanhoorelbeke K; de Groot PG; Maas C
Circulation; 2014 Mar; 129(12):1320-31. PubMed ID: 24449821
[TBL] [Abstract][Full Text] [Related]
11. ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.
Zheng XL
Annu Rev Med; 2015; 66():211-25. PubMed ID: 25587650
[TBL] [Abstract][Full Text] [Related]
12. The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura.
Starke R; Machin S; Scully M; Purdy G; Mackie I
Br J Haematol; 2007 Feb; 136(4):649-55. PubMed ID: 17367414
[TBL] [Abstract][Full Text] [Related]
13. Interactions of von Willebrand factor and ADAMTS13 in von Willebrand disease and thrombotic thrombocytopenic purpura.
Budde U; Schneppenheim R
Hamostaseologie; 2014; 34(3):215-25. PubMed ID: 25010251
[TBL] [Abstract][Full Text] [Related]
14. [ADAMTS13, von Willebrand factor specific cleaving protease].
Veyradier A; Coppo P
Med Sci (Paris); 2011 Dec; 27(12):1097-105. PubMed ID: 22192749
[TBL] [Abstract][Full Text] [Related]
15. Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.
Thomas MR; de Groot R; Scully MA; Crawley JT
EBioMedicine; 2015 Aug; 2(8):942-52. PubMed ID: 26425702
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Prevention of Congenital Thrombotic Thrombocytopenic Purpura in ADAMTS13 Knockout Mice by Sleeping Beauty Transposon-Mediated Gene Therapy.
Verhenne S; Vandeputte N; Pareyn I; Izsvák Z; Rottensteiner H; Deckmyn H; De Meyer SF; Vanhoorelbeke K
Arterioscler Thromb Vasc Biol; 2017 May; 37(5):836-844. PubMed ID: 28254814
[TBL] [Abstract][Full Text] [Related]
17. [anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura].
Matsumoto M
Nihon Rinsho Meneki Gakkai Kaishi; 2013; 36(2):95-103. PubMed ID: 23629429
[TBL] [Abstract][Full Text] [Related]
18. Thrombotic thrombocytopenic purpura-what is new?
Shah N; Sarode R
J Clin Apher; 2013 Feb; 28(1):30-5. PubMed ID: 23420593
[TBL] [Abstract][Full Text] [Related]
19. A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13.
Schiviz A; Wuersch K; Piskernik C; Dietrich B; Hoellriegl W; Rottensteiner H; Scheiflinger F; Schwarz HP; Muchitsch EM
Blood; 2012 Jun; 119(25):6128-35. PubMed ID: 22529289
[TBL] [Abstract][Full Text] [Related]
20. ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal model.
Ostertag EM; Bdeir K; Kacir S; Thiboutot M; Gulendran G; Yunk L; Hayes VM; Motto DG; Poncz M; Zheng XL; Cines DB; Siegel DL
Transfusion; 2016 Jul; 56(7):1775-85. PubMed ID: 27040023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
